Topical Bevacizumab for Preventing Recurrent Pterygium

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Bevacizumab; Ophthalmic Solutions; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.)

• Patients with pterygium who understand and can follow the study protocol.

• Patients of age more than 30 years

Exclusion Criteria:

• Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing.

• Patients who are pregnancy or lactation.

• Patients who have a history of allergy to bevacizumab.

• Patients who have a history of allergy to steroid eye drops